Singular Health announces planned divestment of GeoVR Asset

Singular Health Group Ltd (ASX: SHG) announced that it had signed a share sale agreement to sell of its 50% shareholding in the in the GeoVR Pty Ltd joint venture to its joint venture partner TerraCentric Pty Ltd. The purchase price of AU$500,000 has been offered for the shareholding, subject to standard adjustments in the 90-day due diligence period, along with an ongoing year-to-year license fee of AU$50,000 or a 10% revenue share to access Singular Health’s APIs and Volumetric Rendering Platform.

After completion of this transaction, the company shall continue to support TerraCentric in their future endeavors with GeoVR via the provision of ad-hoc technical, marketing, and corporate services at commercial rates.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au